Donepezil significantly improves abilities in daily lives of female down syndrome patients with severe cognitive impairment: A 24-week randomized, double-blind, placebo-controlled trial

International Journal of Psychiatry in Medicine

Volumn 41, Issue 1, 2011, Pages 71-89

  Kondoh, Tatsuro ^a,b   Kanno, Atsushi ^c   Itoh, Hiroshi ^c   Nakashima, Mikiro ^a   Honda, Ryoko ^a   Kojima, Michio ^d   Noguchi, Mitsuru ^a   Nakane, Hideyuki ^a   Nozaki, Hidetsugu ^e   Sasaki, Hitoshi ^a   Nagai, Toshiro ^f   Kosaki, Rika ^g   Kakee, Naoko ^g   Okuyama, Torayuki ^g   Fukuda, Masafumi ^b   Ikeda, Masayuki ^h   Shibata, Yoshisada ^h   Moriuchi, Hiroyuki ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b Misakaenosono Mutsumi Institute for Persons with Severe Intellectual/Motor Disabilities   (Japan)

^c TOKYO GAKUGEI UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e Jyuai Hospital for Developmental Disabilities   (Japan)

^f Dokkyo Koshigaya Hospital   (Japan)

^g NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^h NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

donepezil; double blind; Down syndrome; overall functioning; placebo controlled study; randomized; severe cognitive impairment

Indexed keywords

DONEPEZIL; LACTOSE; SUCROSE;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FECES COMPOSITION; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MALE; MENTAL FUNCTION; NEUROPATHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADULT; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DOWN SYNDROME; FEMALE; HUMANS; INDANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79551574963     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.41.1.g     Document Type: Article

References (16)

1. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-1289.
2. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Annals of Neurology 1985;18:310-313.
3. Capone G, Goyal P, Ares W, Lannigan E. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. American Journal of Medical Genetics Part C 2006;142C:158-172.
4. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1189.
5. Kish SJ, Distefano LM, Dozic S, Robitaille Y, Rajput A, Deck JH, Hornykiewicz O. [3H] vesamicol binding in human brain cholinergic deficiency disorders. Neuroscience Letters 1990;117:347-352.
6. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Research 1983;280:119-126.
7. Cipriani G, Bianchetti A, Trabucchi M. Donepezil use in the treatment of dementia associated with Down syndrome. Archives of Neurology 2003;60:292.
8. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. The American Journal of Psychiatry 1999;156:1470.
9. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics Part A 2003;116A:111-116.
10. Kishnani PS, Sullivan JA, Walter BK, Spiridiqliozzi GA, Doraiswamy PM, Krishnan KR. Cholinergic therapy for Down's syndrome. Lancet 1999;353:1064-1065.
11. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: Response to donepezil. Archives of Neurology 2002;59:1133-1136.
12. Kondoh T, Amamoto N, Doi T, Hamada H, Ogawa Y, Nakashima M, Sasaki H, Aikawa K, Tanaka T, Aoki M, Harada J, Moriuchi H. Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. The Annals of Pharmacotherapy 2005;39:563-566.
13. Kondoh T, Amamoto N, Doi T, Hamada H, Ogawa Y, Nakashima M, Sasaki H, Aikawa K, Tanaka T, Aoki M, Harada J, Moriuchi H. Dramatic improvement on donepezil in Down syndrome-associated cognitive impairment. Dementia, Helix Review Series 2006;8:6-9.
14. Kondoh T, Nakashima M, Sasaki H, Moriuchi H. Pharmacokinetics of donepezil in Down syndrome. The Annals of Pharmacotherapy 2005;39:572-573.
15. Itoh H, Kanno A. Research concerning the effectiveness of body functionality checklist used as an evaluation scale of the regression and early aging of intellectually disabled persons. Japanese Journal on Support System for Developmental Disabilities 2008;7: 9-17.
16. Wishart JG, Duffy L. Instability of performance on cognitive tests in infants and young children with Down's syndrome. The British Journal of Educational Psychology 1990;60:10-22.